Li Watsek
Stock Analyst at Cantor Fitzgerald
(0.92)
# 3,521
Out of 4,810 analysts
85
Total ratings
29.41%
Success rate
-29.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $31.52 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.50 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $4.14 | - | 1 | Mar 14, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $170 → $200 | $155.50 | +28.62% | 17 | Feb 25, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.40 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.50 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $17.11 | - | 2 | Jan 13, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $5.85 | - | 10 | Dec 9, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $0.79 | - | 7 | Nov 19, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $7.68 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.93 | +305.68% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.07 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.29 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.26 | - | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.03 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.14 | +163.16% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $8.88 | +2,377.48% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.92 | +440.95% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.70 | +2,135.29% | 1 | Aug 12, 2022 |
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $31.52
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.50
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.14
Upside: -
Ascendis Pharma
Feb 25, 2025
Maintains: Overweight
Price Target: $170 → $200
Current: $155.50
Upside: +28.62%
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.40
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.50
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.11
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.85
Upside: -
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.79
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.68
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.93
Upside: +305.68%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.07
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.29
Upside: -
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.26
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.03
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.14
Upside: +163.16%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $8.88
Upside: +2,377.48%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $0.92
Upside: +440.95%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.70
Upside: +2,135.29%